MMV533

MMV533

Translational
-
Human volunteers
(Sanofi)
Asexual blood stages
Uncomplicated malaria treatments and resistance management (TPP-1)
Product vision
  • Uncomplicated malaria and resistance management 
MOA
  • Unknown. Inability to select resistance mutants
Key features
  • Rapid parasite killing in vitro and clearance in vivo
  • Long half-life in human volunteers
  • Predicted human dose of 40 mg for a 12-log parasite killing
Status
  • First-in-human and volunteer infection study ongoing
Next milestone
  • Complete phase I programme (including volunteer infection study)
  • Identification of combination partner
Previously
  • Discovery collaboration between MMV and Sanofi, SAR 441121
  • Full reference name is MMV688533
Project Director
  • Dr Benoît Bestgen